| lamivudine / Generic mfg. |
ChiCTR-OCH-12002141: Entecavir monotherapy versus de novo combination of lamivudine and adefovir for the treatment of naive HBeAg-positive chronic hepatitis B patients with High HBV viral load （the Climber study) |
|
|
| Completed | 4 | 280 | | Lamivudine 100mg po qd, Adefovir Dipivoxil 10mg po qd, for 96 weeks ;Entecvir 0.5mg po qd, for 96 weeks | Departmen of infectious disease, Tongji Hospital, Tongji medical college, Huazhong university of science and technology; Departmen of infectious disease, Tongji hospital, Tongji medical college, Huazhong university of science and technology, Sino-American Shanghai Squibb Pharmaceuticals Ltd. | chronic hepatitis B | | | | |
ChiCTR-TRC-11001258: Efficacy of lamivudine and adefovir de-novo combination therapy or optimal therapy at week 48 in chronic hepatitis B patients |
|
|
| Completed | 4 | 174 | | Adefovir 10mg/d,p.o.qd for 104 weeks or combination with Lamivudine 10mg/d,p.o.qd at 48 weeks.Total treatment time:104 weeks ;Lamivudine(LAM) 100mg/d,p.o.qd for 104 weeks or combination with Adefovir(ADV) 10mg/d,p.o.qd at 48 weeks.Total treatment time:104 weeks ;Lamivudine 100mg/d,p.o.qd +Adefovir 10mg/d,p.o.qd for 104 weeks | Department of Infectious Diseases, Guangdong General Hospital; Level of the institution：, self-financing | Chronic hepatitis B | | | | |
ChiCTR-TRC-08000219: Optimized antiviral therapy in chronic hepatitis B: A randomized, open-label, multicenter, controlled trial |
|
|
| Completed | 4 | 300 | | Giving adefovir only ;Giving adefovir and lamivudine together ;Treated by Lamivudine for 16 weeks and combined with Adefovir when the HBV-DNA >1000 copies/ml | The First Affiliated Hospital of Wenzhou Medical College; GSK, GlaxoSmithKline (China) Investment Co. Ltd | Chronic Hepatitis B | | | | |
ChiCTR-ONRC-11001495: Lamivudine plus adefovir or telbivudine plus adefovir for chronic hepatitis B patients with suboptimal response to adefovir: a prospective controlled study |
|
|
| Completed | 4 | 80 | | Telbivudine 600 mg/day , Adefovir 10 mg/day ;Lamivudine 100 mg/day , Adefovir 10 mg/day | Center of Infctious Diseases, West China Hospital of Sichuan University; Center of Infctious Diseases, West China Hospital of Sichuan University, self-funding | Chronic hepatitis B | | | | |
ChiCTR-TRC-12001980: Multiple-center clinical study of Antiviral Treatment with Nucleoside Analogues on Patients with HBV Associated Acute on Chronic Liver Failure among Multiple Center |
|
|
| Completed | 4 | 800 | | entecavir ;lamivudine | Liver Failure Treatment and Research Center, 302 Military Hospital, Beijing, China; 302 Military Hospital, Beijing, China, The Military Key Clinical Program on the Traditional Chinese Medicine Research and Development; State | HBV associated acute on chronic liver failure | | | | |
ChiCTR-ONRC-12001924: Efficacy and safety of defovir dipivoxil in children with interferon therapy unresponsive and lamivudine- resistance chronic hepatitis B |
|
|
| Completed | 4 | 30 | | Adefovir 0.25mg/kg/d,p.o.qd for three years.ADV dose is not to exceed 10 mg/day. | Affiliated Second Hospital, Southeast University, Nanjing; Affiliated Second Hospital, Southeast University, Nanjing, Self-finance | Chronic hepatitis B | | | | |
2014-000496-64: Viral suppression in Cerebrospinal Fluid in HIV-1 infected patients receiving Ritonavir-boosted Atazanavir plus lamivudine dual theraphy. SCALA study Supresión viral en el líquido cefalorraquídeo en pacientes con infección por VIH-1 que reciben tratamiento antirretroviral con atazanavir potenciado con ritonavir y lamivudina. Estudio SCALA |
|
|
| Ongoing | 4 | 10 | Europe | REYATAZ, NORVIR, LAMIVUDINA EFG | Dr. Daniel Podzamczer Palter. Hospital Univesitari de Bellvitge. Unidad de VIH., Hospital Universitari de Bellvitge - Unidad de VIH | HIV-1 infection Infección por el virus VIH-1, HIV-1 infection Infección por el virus VIH-1, Diseases [C] - Virus Diseases [C02] | | | | |
2014-002281-70: Immune reconstitution in severely immunosuppressed antiretroviral-naive HIV-1?infected patients (<100 CD4+ T cells/?L) taking antiretroviral regimens based on dolutegravir or ritonavir-boosted darunavir (the AdvanZ-4 Trial). Reconstitución inmune en pacientes con infección por el VIH-1 no tratados previamente y con cifras de linfocitos CD4+ inferiores a 100 céls/mm3 que reciben un régimen de fármacos antirretrovirales basado en dolutegravir o darunavir/ritonavir. Estudio AdvanZ-4. |
|
|
| Ongoing | 4 | 108 | Europe | CoatedTablet600 mg de abacavir ( sulfate) 300 mg de lamivudine, PREZISTA 300 mg comprimidos recubiertos con película darunavir, Norvir 100 mg soft tablets, Triumeq, Coated tablet, Capsule, soft, Tablet, KIVEXA( Abacavir 600 mg/ Lamivudine 300 mg) recovered tablets, PREZISTA 300 mg recovered Tablets, NORVIR 100 mg soft Tablets, TRIUMEQ®: Lamivudine(3TC) 300 mg+ Abacavir(ABC) 600 mg + dolutegravir(DGT) 50 mg : 1 comprimido | Fundació Clínic per a la Recerca Biomèdica, ViiV Healthcare UK Limited 980 Great West Road Brentford Middlesex TW8 9GS Reino Unido | tratement HIV infection tratamiento de la infección por HIV, HIV infection infección por HIV, Diseases [C] - Virus Diseases [C02] | | | | |
2015-000274-35: clinical trial to assess the safety, tolerability and efficacy of two dolutegravir-based simplification strategies in HIV-infected patients with prolonged virological suppression. ENSAYO CLÍNICO PARA EVALUAR LA SEGURIDAD, TOLERABILIDAD Y EFICACIA DE DOS ESTRATEGIAS DE SIMPLIFICACIÓN BASADAS EN DOLUTEGRAVIR EN PACIENTES INFECTADOS POR VIH CON SUPRESIÓN VIROLÓGICA SOSTENIDA. |
|
|
| Ongoing | 4 | 450 | Europe | Lamivudine, Efavirenz, nevirapine, J05AX12, Coated tablet, Capsule, hard, Tablet, Prolonged-release tablet, Tivicay, Stribild, TRUVADA, KIVEXA, ZIAGEN, VIREAD, EMTRIVA, ATRIPLA, EVIPLERA, ISENTRESS, RAYATAZ, PREZISTA, KALETRA, NORVIR, INTELENCE, EDURANT, TRIUMEQ | Fundació Lluita contra la SIDA, Fundació Lluita contra la SIDA | Infection with human immunodeficiency virus (HIV). Infección por el virus de la inmunodeficiencia humana (VIH)., HIV infection Infección por VIH, Diseases [C] - Virus Diseases [C02] | | | | |
ChiCTR-ONRC-12002315: Contrast study of Entecavir monotherapy and the de novo combining Lamivudine with Adefovir therapy on HBeAg-positive CHB patients with high viral load |
|
|
| Completed | 4 | 160 | | combination therapy of LAM with ADV ;therapy withETV | NanFang hospital; Xiangya secondary hospital, Guanghui foundation | chronic hepatitis B | | | | |
2004-002633-39: Prospective study of switch to 3TC monotherapy with evaluation of replication capacity in patients with virologic failure and 3TC resistance (a multicenter prospective clinical study within the SHCS) SHCS-Projekt Nr. 408 |
|
|
| Ongoing | 4 | 5 | Europe | Epivir, 3TC, Epivir, Epivir | Prof. Dr. med. Milos Opravil, Universitätsspital Zürich | HIV patients with virological treatment failure due to multi-drug-resistant virus including 3TC resistance | | | | |
2017-004750-42: EFFICACY AND SAFETY OF A SIMPLIFICATION TREATMENT BASED ON DOLUTEGRAVIR AND DARUNAVIR / COBICISTAT VS USUAL TREATMENT IN SUPPRESSED HIV-1-INFECTED PATIENTS WITH MULTIDRUG RESISTANCE. Eficacia y seguridad de Dolutegravir más Darunavir/cobicistat como tratamiento de simplificación frente al tratamiento habitual en pacientes infectados por el VIH-1 virológicamente suprimidos y con resistencia a múltiples fármacos. |
|
|
| Ongoing | 4 | 100 | Europe | lamivudine, Efavirenz, Nevirapine, Film-coated tablet, Coated tablet, Capsule, hard, Tablet, Rezolsta, Tivicay, Ziagen, EMTRIVA, VIREAD, kivexa, Truvada, Intelence, Edurant, Atripla, Eviplera, Reyataz, Prezista, Kaletra, Norvir, Evotaz, Isentress, Stribild, Triumeq, Genvoya, Celsentri, Descovy | FUNDACIÓ LLUITA CONTRA LA SIDA, ViiV Healthcare | HIV-1 VIH-1, HIV infection Infección por VIH, Diseases [C] - Virus Diseases [C02] | | | | |
2019-000199-41: A study to evaluate the impact of the change of antiretroviral treatment from dual therapy to triple therapy on inflammation in HIV+ patients. Estudio para evaluar el impacto del cambio de tratamiento antirretroviral de terapia dual a terapia triple sobre la inflamación en pacientes VIH + |
|
|
| Not yet recruiting | 4 | 234 | Europe | Bictarvy, Tivicay, Epivir, Tablet, Bictarvy, Tivicay, Epivir | Fundación SEIMC-GESIDA, Gilead Sciences, S.L | HIV VIH, HIV VIH, Diseases [C] - Virus Diseases [C02] | | | | |
2019-002733-10: Exploratory, open-label, randomized clinical trial to assess the efficacy of first-line dual vs. triple antiretroviral therapy (art) in hiv-1 reservoir and in peripheral compartments in hiv-infected patients. Ensayo clínico abierto, aleatorizado para evaluar el efecto del tratamiento antirretroviral inicial doble vs.triple en el reservorio del VIH-1 y en tejidos periféricos en pacientes infectados por el VIH-1. |
|
|
| Ongoing | 4 | 44 | Europe | Coated tablet, Tivicay, Descovy, Lamivudine | FUNDACIÓ LLUITA CONTRA LA SIDA, Viiv Healthcare | HIV infection Infección por VIH, HIV infection Infección por VIH, Diseases [C] - Virus Diseases [C02] | | | | |
ChiCTR1900027656: Analysis of the efficacy and safety of dotiapramib in the treatment of HIV infection |
|
|
| Recruiting | 4 | 200 | | Dotiapramib tablets (contains 600 mg of abacavir sulfate, 300 mg of lamivudine and 50 mg of dotilavir sodium) | Chongqing Public Health Medical Treatment Center; Chongqing Public Health Medical Treatment Center, raise independently | AIDS | | | | |
ChiCTR1900020750: A prospective, randomized, non-inferior clinical trial for antiviral therapy optimization programs for AIDS patients |
|
|
| Not yet recruiting | 4 | 200 | | Zidovudine 300mg twice daily / tenofovir 300mg once daily + lamivudine 300mg once daily + nevirapine 200mg twice daily / efavirenz 600mg once daily ;Lopinavir/ritonavir 500mg twice daily + lamivudine 300mg once daily | The Fifth Affilated Hosipital Of Sun Yat-sen University; The Fifth Affiliated Hosipital Of Sun Yat-sen University, Hospital funding and self-finacing | AIDS | | | | |
ChiCTR1900027640: A real world study for a simplified regimen of dolutegravir combined with lamivudine in the treatment of newly infected HIV patients |
|
|
| Not yet recruiting | 4 | 30 | | DTG 50mg +3TC 300mg once a day | The Fifth Affiliated Hosipital Of Sun Yat-sen University; The Fifth Affiliated Hosipital Of Sun Yat-sen University, Hospital funding and self-finacing | HIV/AIDS | | | | |
2021-005347-79: Exposure to Doravirine in people with HIV undergoing weight loss surgery Blootstelling aan doravirine bij mensen met hiv die een operatie voor gewichtsverlies ondergaan |
|
|
| Ongoing | 4 | 8 | Europe | Film-coated tablet, Pifeltro® (100 mg doravirine), Delstrigo® (100 mg doravirine/ 300 mg Lamivudine/ 245 mg Tenofovir Disoproxil Fumarate) | Radboud University Medical Center, Radboud University Medical Center | HIV plus bariatric surgery, HIV and weight loss surgery, Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Surgical Procedures, Operative [E04] | | | | |
ChiCTR2100047490: Rapid initiation of antiviral therapy in newly diagnosed HIV-infected patients based on the simplified protocol of dotiravir / lamivudine |
|
|
| Recruiting | 4 | 100 | | Lamivudine / dotiravir | The First Affiliated Hospital of China Medical University; The First Affiliated Hospital of China Medical University, Study on the optimization and application of AIDS comprehensive treatment plan; AIDS Health Foundation (AHF) | AIDS | | | | |
ChiCTR2300072308: Study on the efficacy and safety of Dolutegravir combined with Lamivudine in the treatment of HIV infections |
|
|
| Completed | 4 | 72 | | None ;None | Chest Hospital of Guangxi Zhuang Autonomous Region (Longtan Hospital of Guangxi Zhuang Autonomous Region); Chest Hospital of Guangxi Zhuang Autonomous Region (Longtan Hospital of Guangxi Zhuang Autonomous Region), Scientific and technological funds provided by Guangxi Liuzhou Science and Technology Bureau, self-owned funds of Chest Hospital of Guangxi Zhuang Autonomous Region (Longtan Hospital) | Acquired immune deficiency syndrome | | | | |
| Completed | 4 | 155 | RoW | Darunavir (DRV) 800 milligram (MG) Oral Tablet, Prezista, Ritonavir 100 MG Oral Tablet, Norvir, RTV, N(t)RTIs, Nucleoside/nucleotide reverse transcriptase inhibitors [N(t)RTIs], Dolutegravir 50 MG Oral Tablet, Tivicay, DTG, TDF 300 MG Oral Tablet, tenofovir disoproxil fumarate, Viread, 3TC 300 MG Oral Tablet, lamivudine, FTC 200 MG Oral Cap, Emtriva, emtricitabine | Kirby Institute | HIV Infections | 01/24 | 01/24 | | |
| Active, not recruiting | 4 | 100 | RoW | TLD - Tenofovir Disoproxil Fumarate / Lamivudine / Dolutegravir, Acriptega | University of Witwatersrand, South Africa, Bill and Melinda Gates Foundation | HIV Prevention | 06/26 | 08/26 | | |
NCT06503796: Antiviral Therapy in Infants With HBV Infection |
|
|
| Not yet recruiting | 4 | 60 | RoW | Lamivudine, Interferon | Beijing 302 Hospital | HBV | 11/25 | 11/26 | | |
ChiCTR2300069528: A randomized, open-label, controlled clinical trial of lamivudine in the treatment of adults with ultra-early novel coronavirus infection |
|
|
| Suspended | 4 | 1000 | | Symptomatic treatment+lamivudine 10mg qd*5 days ;Symptomatic treatment+azvudine 5mg qd*5 days | Emergency Department of Rongxian People's Hospital; Rongxian People's Hospital, Self-financing | 2019 novel coronavirus infection | | | | |
ChiCTR-TRC-08000172: Randomized controlled trial of nucleot(s)ide analogues treatment for postoperative HBV-related HCC |
|
|
| Completed | 3 | 200 | | Regular integrated postoperative therapy ;Antiviral therapy (Lamivudine (100 mg/day) (GlaxoSmithKline, Beijing, China) was used as of choice antiviral treatment. Adefovir dipivoxil (10 mg/day) (GlaxoSmithKline) plus lamivudine or entecavir (0.5 mg/day) (Sino-American Squibb, Shanghai, China) was applied if the patients presented drug-resistance) and regular integrated postoperative therapy. | Eastern Hepatobiliary Hospital, Second Military Medical University; Level of the institution：, Self-financing | Hepatocellular carcinoma | | | | |
ChiCTR-TRC-12002121: Preventive use of lamivudine in postgastrectomy adenocarcinoma patients carrying HBV to prevent from severe liver damage and viral activation |
|
|
| Completed | 3 | 60 | | lamivudine ;Radiotherapy combined with Chemotherapy that contains oxaliplatin | West China Hospital, Sichuan University; Level of the institution：, Hospital funding | gastric cancer and HBV | | | | |
2005-000005-65: Comparación de dos alternativas de combinación de nucleósidos, en pacientes infectados por el HIV-1 con supresión virológica mantenida y en tratamiento con lamivudina (3TC). Estudio aleatorizado, multicéntrico y abierto. |
|
|
| Ongoing | 3 | 300 | Europe | Kivexa, Viread, Emtriva, GI 265235 + GR 109714, Viread, Emtriva, Viread, Emtriva | Servicio de Infecciones. Hospital Clínic de Barcelona | Chronic HIV infection | | | | |
2020-003951-13: Dual therapy in HIV patients in 4 days a week versus 7 days a week Bithérapie chez des patients HIV en 4 jours sur 7 versus 7 jours sur 7 |
|
|
| Not yet recruiting | 3 | 440 | Europe | Film-coated tablet, TIVICAY, EPIVIR, PREZISTA, EDURANT, NORVIR | INSERM-ANRS, ANRS | HIV infection Infection par le VIH, HIV infection Infection par le VIH, Diseases [C] - Virus Diseases [C02] | | | | |
NCT01936233: Clinical Study of Antiviral and Aspirin Treatment in Liver Cancer After Radical Surgery |
|
|
| Recruiting | 3 | 112 | RoW | Aspirin, Lamivudine | Fudan University | Hepatocellular Carcinoma, Recurrence | 12/21 | 12/23 | | |
2022-001437-36: ITACO study and the Analytical Antiretroviral Treatment Interruption study (ITACO-ATI) Studio ITACO e studio sull'interruzione del Trattamento Antiretrovirale (ITACO-ATI) |
|
|
| Not yet recruiting | 3 | 61 | Europe | ODEFSEY, REZOLSTA, BIKTARVY, Triumeq, Edurant, Tivicay, Descovy, Symtuza, Dovato, Epivir, [na], Film-coated tablet, ODEFSEY - 200 MG/25 MG/25 MG- COMPRESSA RIVESTITA- USO ORALE- FLACONE (HDPE) 30 COMPRESSE, REZOLSTA - 800 MG/ 150 MG- COMPRESSA RIVESTITA CON FILM- USO ORALE-FLACONE (HDPE)- 30 COMPRESSE, Biktarvy, TRIUMEQ - 50MG/600MG/300 MG - COMPRESSA RIVESTITA CON FILM - USO ORALE - FLACONE HDPE - 1 FLACONE 30 COMPRESSE, EDURANT - 25 MG - COMPRESSA RIVESTITA CON FILM - USO ORALE - FLACONE (HDPE) 30 COMPRESSE, TIVICAY - 50 MG - COMPRESSA RIVESTITA CON FILM - USO ORALE - FLACONE (HDPE) - 30 COMPRESSE, DESCOVY - 200 MG/10 MG- COMPRESSA RIVESTITA CON FILM- USO ORALE- FLACONE (HDPE)- 30 COMPRESSE, Symtuza, DOVATO - 50 MG / 300 MG - COMPRESSA RIVESTITA CON FILM - USO ORALE - FLACONE (HDPE) - 30 COMPRESSE, EPIVIR - 300 MG 1 FLACONE 30 COMPRESSE RIVESTITE CON FILM USO ORALE | IRCCS, OSPEDALE PEDIATRICO BAMBINO GESÙ DI ROMA, NIH (Johns Hopkins University) | perinatally HIV infection Infezione da HIV perinatale, perinatally HIV infection Infezione da HIV perinatale, Diseases [C] - Immune System Diseases [C20] | | | | |
AXIS, NCT06138600: Acceptability and Feasibility of Injectable Cabotegravir Pre-exposure Prophylaxis (PrEP) Versus Oral PrEP in Routine Care up to 15 Months in Private Pharmacies in South Africa |
|
|
| Active, not recruiting | 3 | 200 | RoW | Cabotegravir Injection [Apretude], Apretude, Tenofovir disoproxil fumarate / emtricitabine (or lamivudine), Tenemine | University of Witwatersrand, South Africa, ViiV Healthcare | HIV Infections | 10/25 | 01/26 | | |
ChiCTR2100051605: Randomized, Double-Blind, Double-Dummy, Phase III Study to Evaluate Switching From a Regimen of Two Nucleoside Reverse Transcriptase Inhibitors (NRTI) Plus a Nonnucleoside Reverse Transcriptase Inhibitor (NNRTI) to a Fixed Dose Combination(FDC) of ACC007 Versus Elvitegravir, in Virologically-Suppressed, HIV-1 Infected Participants&# |
|
|
| Recruiting | 3 | 762 | | Tablet; Specification: Each tablet contains 150 mg of ACC007, 300 mg of lamivudine and 300 mg of tenofovir fumarate; it is orally administered on an empty stomach every day ;Tablet; Specification: Each tablet contains 150 mg of elvitegravir, 150 mg of cobicistat, 200 mg of emtricitabine and 10mg of tenofovir alafenamide fumarate; it is orally administered with food every day | Beijing Ditan Hospital, Capital Medical University; Nanjing Accelas Pharmaceutical Co., Ltd. and Jiangsu Aidea Pharmaceutical Co., Ltd., self-funded | HIV/AIDS | | | | |
D3 (Penta21), NCT04337450: DTG/3TC Fixed Dose Formulations for the Maintenance of Virological Suppression in Children with HIV Infection Aged 2 to <15 Years Old |
|
|
| Recruiting | 2/3 | 370 | Europe, RoW | Dolutegravir (DTG) and lamivudine (3TC), SOC | PENTA Foundation, MRC CTU at UCL, AMS-CMU/IRD (PHPT), Chris Hani Baragwanath Academic Hospital, Durban International Clinical Research Site, Hospital Universitario 12 de Octubre, Prapokklao Hospital, Chantaburi, Chiangrai Prachanukroh Hospital, Nakornping Hospital, Khon Kaen Hospital, Kalasin Hospital, Joint Clinical Research Center, MU-JHU CARE, Baylor College of Medicine, Great Ormond Street Hospital for Children NHS Foundation Trust, University Hospital Birmingham NHS Foundation Trust, Department of Clinical Pharmacy, University Medical Centre St Radboud, The Netherlands., Advanced Pathogens Diagnostics Unit, University College London Hospitals, Centre for Health Economics, University of York, Department of Molecular and Clinical Pharmacology, University of Liverpool, Chang Mai Univerity, St Mary's Hospital, London | HIV Infections | 09/25 | 09/25 | | |
ACTRN12605000742673: AVX754 (nucleoside reverse transcriptase inhibitor) to treat drug resistant HIV |
|
|
| Recruiting | 2 | 60 | | | Avexa Ltd, Avexa Ltd | HIV Infections | | | | |
ChiCTR-TRC-11001683: Perioperative hepatitis B virus load control strategies and molecular mechanisms of anti-recurrence and metastasis in hepatic cancer |
|
|
| Completed | 2 | 200 | | Give lamivudine antiviral therapy ;Give lamivudine and foscarnet antiviral therapy ;Give lamivudine and adefovir dipivoxil antiviral therapy ;Give entecavir antiviral therapy | 1st Affiliated Hospital of Medical College, Zhejiang University; Zhejiang University School of Medicine, self | hepatic cancer and hepatitis B virus | | | | |
| Active, not recruiting | 2 | 97 | RoW | Lamivudine Oral Solution | ANRS, Emerging Infectious Diseases, Institut National de la Santé Et de la Recherche Médicale, France, Centre Muraz | HIV-1 | 03/22 | 03/22 | | |
| Terminated | 2 | 85 | Europe, Canada, US, RoW | GSK3640254, Dolutegravir, Lamivudine capsules, Lamivudine tablets | ViiV Healthcare, Syneos Health | HIV Infections | 11/22 | 05/23 | | |
NCT06519357: A Single-center, Self-controlled, Prospective Case Series Pilot Study to Assess the Effect of Lamivudine (3TC) on Neurocognitive Impairment Biomarkers and Type-I IFN (Interferon)-Stimulated Genes in the Plasma of Patients With Mild Cognitive Impairment (MCI) |
|
|
| Recruiting | 2 | 25 | Europe | Lamivudine 300 MG | Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia, IrsiCaixa | Mild Cognitive Impairment | 04/25 | 06/25 | | |
NCT04696575: Lamivudine in Combination With Chemoimmunotherapy for the Treatment of Extensive Stage Small Cell Lung Cancer |
|
|
| Recruiting | 2 | 28 | US | Atezolizumab, MPDL 3280A, MPDL 328OA, MPDL-3280A, MPDL3280A, MPDL328OA, RG7446, RO5541267, Tecentriq, Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Etoposide, Demethyl Epipodophyllotoxin Ethylidine Glucoside, EPEG, Lastet, Toposar, Vepesid, VP 16, VP 16-213, VP-16, VP-16-213, VP16, Lamivudine, (-)-BCH-189, 3TC, Epivir, GR109714X, LAM | Roswell Park Cancer Institute | Extensive Stage Lung Small Cell Carcinoma | 07/25 | 07/26 | | |
ART-AD, NCT04552795: Pilot Study to Investigate the Safety and Feasibility of AntiRetroviral Therapy for Alzheimer's Disease |
|
|
| Completed | 1/2 | 12 | US | 3TC, Epivir, lamivudine | The University of Texas Health Science Center at San Antonio, Owens Medical Research Foundation | Alzheimer Disease, Early Onset | 05/23 | 11/23 | | |
| Recruiting | 1/2 | 24 | US | Lamivudine, PD-L1 Blocker | Thomas Marron | Relapsed/Refractory Solid Tumors | 07/27 | 07/27 | | |
ChiCTR-OIC-16008249: Bioequivalence of Lamivudine to healthy Chinese volunteers in a single-dose study |
|
|
| Recruiting | 1 | 48 | | Group A fasting T-R ;Group B fasting R-T ;Group A after the meal T-R ;Group B after the meal R-T | Beijing Shijitan Hospital Capital Medical University; Lonzeal Pharmaceutical Co., Ltd, Lonzeal Pharmaceutical Co.,Ltd | Chronic hepatitis B | | | | |
NCT06056596: Lamivudine and Plasma Markers of Inflammation in Retinal Detachment |
|
|
| Terminated | 1 | 2 | US | Lamivudine 300 MG, Placebo | University of Wisconsin, Madison | Retinal Detachment, Rhegmatogenous Retinal Detachment | 09/24 | 09/24 | | |
ChiCTR-TRC-09000638: A Study on the viral kinetics of different regimes of Pegylated Interferon and Lamivudine combination therapy in HBeAg Positive Chronic Heptatitis B |
|
|
| Completed | N/A | 30 | | PEG-Intron A 100mcq sc once weekly, Lamivudine 100mg QD treatment period 104 weeks (include 32 doses of PEG-Intron A and 96 or 104 weeks Lamivudine) versus one year treatment of Lamivudine 100mg QD | Schering-Plough; None, Hepatitis Research Fund | Viral Diseases | | | | |
ChiCTR-TRC-12002962: A clinical study on Diwuyanggan capsule in treating HBeAg-negative chronic hepatitis B |
|
|
| Completed | N/A | 144 | | Diwuyanggan capsule orally taken three times daily ;Antiviral treatment group:the nucleoside analogues (Entikawei, Adefovir Dipivoxil Tablets, Lamivudine and so on) ;Diwuyanggan capsule and the nucleoside analogues | Hubei province hospital of Traditional Chinese Medicine; Hubei province hospital of traditional Chinese medical, National Natural Science Foundation of China, State Administration of Traditional Chinese Medicine | Chronic hepatitis B | | | | |
ChiCTR-OCH-14004522: Treatment effect and drug-resistant mutations in Chinese AIDS patients switching to second-line antiretroviral therapy |
|
|
| Completed | N/A | 195 | | Tenofovir (TDF) + Kaletra (ritonavir and lopinavir mixture) + lamivudine (3TC)combination antiretroviral therapy ;Tenofovir (TDF) + Kaletra (ritonavir and lopinavir mixture) + lamivudine (3TC)combination antiretroviral therapy | Key Laboratory of AIDS Immunology of National Health and Family Planning Commission, Department of Laboratory Medicine, The First Affiliated Hospital, China Medical University; Disease Prevention and Control Center of Henan Province, the Twelfth Five-Year Project on Tackling Key Problems of National Science and Technology (2012ZX10001002-002-013) | AIDS | | | | |
ChiCTR1900024611: Dual therapy with lopinavir/ritonavir plus lamivudine could be an effective alternative for antiretroviral-therapy-naive adults with HIV-1 infection in resource-limited settings: planned 144 week, a randomized, open-label and non-inferiority study from China |
|
|
| Recruiting | N/A | 200 | | Dual-therapy of lopinavir/ritonavir (LPV/r) plus 3TC (DT group) ;triple-therapy regimen containing tenofovir (TDF), 3TC plus efavirenz (EFV) | Guangzhou Eighth People's Hospital; Level of the institution：, no | AIDS | | | | |
| Completed | N/A | 48 | | Tablet; Specification: Each tablet contains 150 mg of ACC007, 300 mg of lamivudine and 300 mg of tenofovir fumarate; it is orally administered on an empty stomach, 1 tablet per cycle, 2 cycles in total. ;Tablet; Specification: ACC007 2 tablets + lamivudine 1 tablet + tenofovir fumarate 1 tablet; oral administration on an empty stomach, 2 tablets per cycle, 2 cycles in total. | Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School; Jiangsu Aidea Pharmaceutical Co., Ltd., Self-financing | HIV/ADIS | | | | |
ChiCTR2300075493: Multicenter clinical study of new antiviral therapy for HIV/AIDS patients co-infected with tuberculosis |
|
|
| Recruiting | N/A | 200 | | After 2 weeks of anti-tuberculosis treatment, antiviral treatment began. The triple antiviral treatment regimen consisted of tenofovir (300mg per dose, once daily), lamivudine (300mg per dose, once daily), and efaviren (600mg per dose, once daily before bedtime). The patient was followed up for 48 weeks.; After 2 weeks of anti-tuberculosis treatment, antiviral therapy was initiated with a dual antiviral treatment regimen consisting of dotiravir (50mg per dose, once daily) and lamivudine (300mg per dose, once daily), followed up for 48 weeks. If the subjects are randomly assigned to the dual antiviral treatment group, the dose of dotiravir needs to be doubled during the administration of rifampicin (i.e. 50mg per dose, taken orally twice a day, with a 12 hour interval between the two doses). | Shanghai Public Health Clinical Center; Shanghai Public Health Clinical Center, Science and Technology Commission of Shanghai Municipality | HIV/AIDS co-infected with tuberculosis | | | | |
ChiCTR2400084217: Reactivation of hepatitis B virus in HIV patients with HBcAb positive/HBsAg negative after switching to a two-drug regimen lamivudine-based treatment |
|
|
| Not yet recruiting | N/A | 212 | | None; None | Beijing Ditan Hospital; Ditan hospital, Beijing Municipal Finance Special Funds and Self-financing Funds | HIV/AIDS | | | | |
NCT00476606: A Prospective Cohort of Children With HIV Infection |
|
|
| Active, not recruiting | N/A | 500 | RoW | Zidovudine, Stavudine, Didanosine, Lamivudine, Nevirapine, Efavirenz, LPV/r, Saquinavir, Indinavir, Ritonavir, Nelfinavir | The HIV Netherlands Australia Thailand Research Collaboration, Khon Kaen University | HIV Infections | 06/24 | 06/24 | | |
NCT05332470: A Real-world Study of Lamivudine and Dotiravir Sodium Tablets in the Treatment-naïve HIV-1 Infected Patients |
|
|
| Not yet recruiting | N/A | 200 | NA | Lamivudine and Dotiravir Sodium Tablets, Dovato | Peking Union Medical College Hospital | HIV-1-infection | 06/22 | 05/25 | | |
